Inhibikase Therapeutics enters ATM equity distribution agreement for up to $9.8M through Piper Sandler

Inhibikase Therapeutics, Inc.

Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.
Agent receives 3.0% commission on gross proceeds; expense reimbursement up to $75k upfront + $15k per quarter.
Sales made under existing shelf registration (Form S-3, File 333-262551) effective Feb 2022.
Company has no obligation to sell; may suspend or terminate the agreement at any time.
Customary representations, warranties, and indemnification provisions included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.